Therapy Resistant Non-Small Cell Lung Cancer: The role of Molecular Tumor Boards for Clinical Management.
Léon C. van Kempen
Dept of Pathology,
Laboratory for Molecular Pathology
University Medical Center Groningen
Groningen, The Netherlands
The molecular landscape of non-small cell lung cancer (NSCLC) is continuously changing under the selective pressure of targeted therapies. In-depth molecular profiling of repeat biopsies in a diagnostic setting reveals known and unknown mechanisms of therapy resistance. A multidisciplinary molecular tumor board provides clinicians with an expert opinion and subsequent treatment advice. Cases will be presented that demonstrate the value of the modeling of drug interactions with mutated proteins that can predict therapy response.